Edition:
United Kingdom

People: Biohaven Pharmaceutical Holding Company Ltd (BHVN.N)

BHVN.N on New York Stock Exchange

38.04USD
5:39pm BST
Change (% chg)

$0.62 (+1.66%)
Prev Close
$37.42
Open
$38.36
Day's High
$38.70
Day's Low
$37.77
Volume
40,229
Avg. Vol
192,787
52-wk High
$67.86
52-wk Low
$29.17

Childs, John 

Mr. John W. Childs serves as Director of the Company. Mr. Childs has served as a director of our Company since January 2014. Mr. Childs served as chairman and partner of J.W. Childs Associates, L.P., a private equity firm, from 1995 to 2019. From 1991 to 1995, Mr. Childs was senior managing director of Thomas H. Lee Partners and from 1987 to 1990 was a managing director of Thomas H. Lee Partners. Prior to 1987, Mr. Childs was associated with the Prudential Insurance Company of America (“Prudential”) for 17 years where he held various executive positions in the investment area, ultimately serving as senior managing director in charge of the Capital Markets Group, at which time he was responsible for Prudential’s approximately $77 billion fixed income portfolio, including all of the Capital Markets Group’s investments in leveraged acquisitions. He is currently a director of Realm Cellars, Omax Health Inc., Kleo Pharmaceuticals, Inc., and is on the Board of Managers of the Jane Coffin Childs Memorial Fund for Medical Research. Mr. Childs holds a B.A. from Yale University and an MBA from Columbia University. We believe that Mr. Childs’ extensive operational and capital markets experience qualifies him to serve as a member of our Board.

Basic Compensation

Total Annual Compensation, USD 621,360
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 38,777
Fiscal Year Total, USD 660,137

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Declan Doogan

706,360

Vlad Coric

7,854,000

James Engelhart

3,217,070

Kimberly Gentile

2,784,540

Charles Conway

2,792,860

Robert Berman

521,060
As Of  31 Dec 2018